Scientists have engineered mice with brains containing substantial amounts of human cerebral tissue, marking a potential advance in understanding and treating neurological and developmental disorders. The research, led by Sergiu Pasca, a psychiatry professor at Stanford University, involved transplanting lab-grown human brain cells into genetically modified mice lacking key parts of their own brain, creating what the team terms “xenocortical” mice.
To accommodate the human tissue, the researchers bred mice with severely reduced cerebral cortex and hippocampus development—regions critical to memory and cognition. This modification created space for the human brain organoids, grown from stem cells originally derived from donated skin cells, to integrate and form connections with the rodent nervous system. The mice developed with approximately half their brain volume composed of human neurons, though these cells were immature, roughly equivalent to mid-gestation human brain tissue.
The study, published in Nature, showed that mice with the human brain tissue behaved differently under certain conditions. For example, when subjected to a five-hour low-oxygen environment—intended to mimic a cause of cerebral palsy—the xenocortical mice exhibited greater difficulty maintaining balance and gait compared to unmodified mice. While the human tissue did not enhance overall function, the animals showed modest improvements in some cognitive and motor challenges linked to their genetic deficits.
Pasca highlighted this model’s potential for investigating a variety of disorders, including schizophrenia, epilepsy, intellectual disability, cerebral palsy, and rare dementias. By using patient-derived cells to grow brain tissue in living animals, scientists can observe how diseases develop and test possible drug interventions in a more physiologically relevant context than traditional lab-grown organoids alone.
The approach has drawn both interest and caution from experts. Madeline Lancaster, a group leader at the MRC Laboratory of Molecular Biology in Cambridge, noted that the model may be especially useful for studying disorders requiring a whole-animal context but expressed reservations about its ability to fully replicate natural human brain development given the artificial environment. Many researchers prefer growing brain organoids in vitro to reduce animal use, while acknowledging that some experiments may necessitate live animal models.
The research has been subject to extensive ethical review, given concerns surrounding the welfare of animals hosting human tissue and questions about the potential for consciousness or pain perception in chimeric brains. Emily Jackson, law professor at the London School of Economics and chair of a bioethics report on neural organoids, emphasized the importance of ongoing monitoring to assess animal welfare.
Overall, scientists describe the work as a technical breakthrough offering a new avenue to explore brain diseases and developmental conditions that have historically been challenging to study due to the complexity and inaccessibility of the human brain. Yet, the research also underscores the continuing need for ethical oversight and careful consideration of the scientific goals to justify this type of animal experimentation.